ATXI (Avenue Therapeutics Inc.) Net earnings per share (EPS TTM)

Avenue Therapeutics focuses on developing treatments for neuropathologies and acute pain. The EPS YoY TTM shift metric visualizes profit dynamics, where 61.70 represents the current level of the metric. Capital optimization is driven by FDA approval of new drugs and the utilization of patent protection against opioids, which creates significant barriers to entry for new players in the sector.
Avenue Therapeutics - analytical breakdowns and key metrics (ATXI)

This indicator reflects the percentage change in net income per share over the last twelve months relative to the same period last year. The calculation is based on a comparison of rolling totals, identifying profitability trends and the impact of costs. By analyzing the annual growth dynamics of EPS (TTM), an investor assesses capital resilience to market fluctuations. For Avenue Therapeutics (ATXI), this metric correlates with the efficiency of R&D laboratories. The stable operation of analytical equipment and seamless contract manufacturing of drugs create the foundation for a future positive transformation of earnings.